Biotech of the Week: Avexxin, reducing inflammatory diseases from far up in Norway

13/05/2016 - 1 minute

We’re not going particularly far this week and we aren’t even leaving Scandinavia! From Stockholm, we are crossing the border to Norway and go up North. Sadly it’s not the see the Northern Lights but to visit Trondheim, where Avexxin, our Biotech of the Week is located.


City: Trondheim (Norway)

Founded: 2005

Employees: 8 (as of 12/2014)

Financial Data: N/A

CEO: Mikael Ørum


Mission: Based in Trondheim, clinical stage pharmaceutical company Avexxin specialises on the development of novel, first-in-class small molecules for a treatment of a range of inflammatory conditions, and chronic diseases.

Avexxin’s current pipeline includes compounds against psoriasis and related autoimmune diseases, including rheumatoid arthritis and glomerulonephritis (Kidneys). They have even been previously tested and proven successful against various cancer models.

The new chemical entity in use targets the group IVa cPLA2 enzyme regulating the cytokine-induced activation of the pro-inflammatory transcription factor NF-κB.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member